Hydroxyurea therapy for sickle cell disease in community-based practices: A survey of Florida and North Carolina hematologists/oncologists

American Journal of Hematology

Volumn 79, Issue 2, 2005, Pages 107-113

  Zumberg, Marc S ^a   Reddy, Suresh ^a   Boyette, Robert L ^a   Schwartz, Robert J ^b   Konrad, Thomas R ^b   Lottenberg, Richard ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cross sectional; Hydroxyurea; Sickle cell; Survey

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; NARCOTIC ANALGESIC AGENT;

ACUTE CHEST SYNDROME; AGE; BLOOD CELL COUNT; BONE MARROW TOXICITY; CARCINOGENICITY; CHRONIC PAIN; CLINICAL PRACTICE; COMMUNITY HOSPITAL; CONTRACEPTION; DRUG COST; DRUG MONITORING; DRUG SAFETY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MEAN CORPUSCULAR VOLUME; MEDICAL SPECIALIST; PATIENT COMPLIANCE; PRESCRIPTION; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUESTIONNAIRE; RETICULOCYTE COUNT; REVIEW; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; STROKE; ULCER; UNITED STATES; UNIVERSITY HOSPITAL;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; COMMUNITY MEDICINE; CROSS-SECTIONAL STUDIES; FLORIDA; HEMATOLOGY; HUMANS; HYDROXYUREA; MEDICAL ONCOLOGY; NORTH CAROLINA; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 20044371448     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20353     Document Type: Review

References (33)

1. Rosse WF, Narla M, Petz LD, Steinberg MH. New views of sickle cell disease pathophysiology and treatment. Hematology (Am Soc Hematol Educ Program) 2000;2-17.
2. Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Br J Haematol 2003;120(2):177-186.
3. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology cation transport and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994;83:553-560.
4. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996;7(6):300-326.
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332(20):1317-1322.
6. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996;88(6):1960-1964.
7. Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000;64(1):26-31.
8. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. J Am Med Assoc 2003;289(13):1645-1651.
9. Ferguson RP, Arun A, Carter C, et al. Hydroxyurea treatment of sickle cell anemia in hospital-based practices. Am J Hematol 2002;70(4):326-328.
10. Trials assessing innovative strategies to improve clinical practice through guidelines in heart, lung, and blood diseases. Report no. RFA-HL-01-011. Release date: 6-29-2001. Bathesda, MD: National Heart, Lung, and Blood Institute.
11. The American Association for Public Opinion Research (AAPOR). Standard definitions: final dispositions of case codes and outcome rates for surveys. Lenexa, KS: AAPOR; 2000.
12. Clinical alert: Drug treatment for sickle cell disease. Release date: January 30, 1995. Bathesda, MD: National Heart, Lung, and Blood Institutes (NHBLI); 1995.
13. Anonymous. Hydroxyurea marketed for sickle cell anemia. Am J Health Syst Pharm 1998;55:875.
14. rd edition. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1995.
15. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34(1):17-23.
16. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332(17):1132-1136.
17. Najean Y, Rain JD. Treatment of polycythemia vera: use of P-32 alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 1997;89(7):2319-2327.
18. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84(12):4064-4077.
19. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90(9):3370-3377.
20. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110(3):577-583.
21. Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996;52(1):42-46.
22. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91(2):616-622.
23. Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994;52(3):134-139.
24. Liozon E, Brigaudeau C, Trimoreau F, et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997;39(1):11-18.
25. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequel of therapy, or a combination of both? Semin Hematol 2004;41(2 Suppl 3):15-17.
26. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-3632.
27. Rauch A, Borromeo M, Ghafoor A. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia [Abstract]. Blood 1999;94:415a.
28. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med 2000;133(11):925-926.
29. Chaine B, Neonato M-G, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 2001;137:467-470.
30. O'branski EE, Ware RE, Prose NS, Kinney TR. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. J Am Acad Dermatol 2001;44(5):859-861.
31. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103(6):2039-2045.
32. Sirieix M-E, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea. Arch Dermatol 1999;135:818-820.
33. Prasad R, Hasan S, Castro O, Perlin E, Kim K. Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises. Am J Med Sci 2003;325(3):107-109.